Profound Medical Completes First Commercial BPH Treatment With New TULSA-AI Volume Reduction Module

Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign prostatic hyperplasia/BPH treatment using its TULSA-PRO system with the new TULSA-AI Volume Reduction Module.

The procedure was performed on June 9 by Dr. Naveen Kella, the Founder of The Urology Place and an Adjunct Assistant Professor for the UT Health Science Center, San Antonio. BPH is a non-cancerous enlargement of the prostate gland common in aging men, which often leads to lower urinary tract symptoms/LUTS. Current BPH treatments, like transurethral resection of the prostate/TUR, have largely remained unchanged for 100+ years and carry risks of complications like bleeding, erectile dysfunction, loss of ejaculation, and extended hospital stays.

The TULSA procedure, performed with the TULSA-PRO system, is designed to be an incision- and radiation-free one-and-done treatment, which is typically completed in a few hours without requiring a hospital stay or causing bleeding.

The TULSA-PRO system, which received 510(k) clearance in 2019, employs real-time MR guidance and AI-enhanced planning for precise ablation of diseased prostate tissue by gently heating it to 55-57°C via sound absorption technology. The newly introduced TULSA-AI Volume Reduction module specifically streamlines TULSA procedures for BPH by reducing the volume of obstructive prostate tissue. Before the new module, the TULSA-PRO system was already used globally by surgeons for BPH.

Profound Medical Corp. (NASDAQ:PROF) is a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image-guided ablation of diseased tissue in Canada, Germany, the US, and Finland.

While we acknowledge the potential of PROF as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.